Skip to main content

Table 2 Response rate

From: Phase II clinical trial of sorafenib plus interferon-alpha treatment for patients with metastatic renal cell carcinoma in Japan

Best response

N = 42

CR

1

PR

10

SD

22

PD

6

NE

3

ORR (%)

26.2

DCR (%)

78.5

  1. CR complete response, PR partial response, SD stable disease, PD progressive disease, NE not evaluated, ORR objective response rate, DCR disease control rate